key: cord-0991658-mf9nnfnq
authors: Bolislis, Winona Rei; De Lucia, Maria Lucia; Dolz, Felipe; Mo, Runyi; Nagaoka, Makoto; Rodriguez, Heraclio; Woon, MayLi; Yu, Wei; Kühler, Thomas C.
title: Regulatory agilities in the time of COVID-19: Overview, Trends and Opportunities
date: 2020-11-30
journal: Clin Ther
DOI: 10.1016/j.clinthera.2020.11.015
sha: 10d8981113c8aaa834d003fd3187b58aa5ed66fe
doc_id: 991658
cord_uid: mf9nnfnq

Purpose Critical steps have been adopted by health and regulatory authorities around the world to respond to the COVID-19 pandemic. The authors aim to highlight these by providing an overview of the regulatory approaches adopted during the onset of the pandemic, provide an assessment of observed trends, and offer some reflections and proposals to leverage learnings and opportunities from this current pandemic. Methods The authors collected and classified documents and informational materials relating to the regulatory environment around the development and management of medical products during the COVID-19 pandemic. These have been sourced from official websites and press releases of health authorities and international bodies from selected markets across the globe and covers the period between January to July 2020. Additional information to support this study has been gathered through a literature review and analysis of related data available in the public domain and complemented with our own experience in the company. Findings Communication has been vital in addressing the impact of COVID-19. More than 1700 documents and informational materials have been gathered relating to health or regulatory response to the COVID-19 pandemic. Out of these 1705 documents, around 20% or 343 have been identified as regulatory agilities. These agile approaches have been classified into three major categories namely where health and regulatory authorities have: a) facilitated product management across the entire lifecycle, notably in expediting medical product use, ensuring the continuity of clinical trials, and addressing supply chain issues; b) strengthened international cooperation; and c) addressed regulatory burden with the adoption of electronic and digital tools. Implications While many of these regulatory measures have been introduced temporarily as a response to the COVID-19 crisis, there are opportunities to leverage learnings from these approaches in order to collectively achieve more efficient regulatory systems to mitigate and address the impact of the COVID-19 crisis and further future-proof the regulatory environment.

A global pandemic of the magnitude of COVID-19 has a significant impact, even transformative, in a number of ecosystems. This is particularly poignant in the healthcare ecosystem, and within it those involved in developing COVID-19-related treatments, medical devices, and vaccines, but also those who are ensuring that already approved medical products continue to remain available to patients around the world for their continued or future benefit.

To address the impacts of COVID-19 and simultaneously ensure continuity of development of non-COVID treatments, regulators have demonstrated significant regulatory agility while maintaining high standards for quality, safety, and effectiveness. 1 Regulators have adopted and made public critical steps to raise awareness and provide guidance to stakeholders on how to respond and navigate through the current pandemic. In doing so, they have demonstrated tremendous agility. This paper provides a comprehensive overview and an assessment of these steps and approaches made available by regulatory authorities. Through this, we include J o u r n a l P r e -p r o o f reflections on some lessons learned and how to leverage solutions that continue to provide value-add, streamline regulatory processes, or address regulatory burden for the benefit of all stakeholders; from the medical product developers through the regulators to the HCP for the ultimate benefit of patients.

As of July 2020, we have collected and classified 1705 documents or informational materials related to the regulatory environment around the development and management of medical products concerning the COVID-19 pandemic. Some of these documents refer to actions, initiatives or exceptional approaches where health or regulatory authorities have either a) advanced already existing initiatives aiming at agile and responsive regulatory systems and processes or b) have introduced new and innovative ways to expedite and improve such processes. For the purpose of this paper, we refer to regulatory agility as the willingness of authorities to take quick action within the accepted regulatory framework to ensure that the regulatory ecosystem swiftly responds to the challenges imposed by the pandemic for the ultimate benefit of patients and society as a whole.

The data collected for this analysis were extracted from COVID-19-related information (guidance, guidelines, notices, administrative communications, etc.) issued by health authorities in selected markets and regional and international bodies The documents were then classified by zone, country, regulatory authority, information format, and topic area. Based on this list, we identified those that refer to regulatory approaches and have used these as a basis to extract trends, learnings, and potential ways forward. Additional information to put trends and learnings into perspective, were gathered through a literature review and analysis of related data available in the public domain, as well our own experiences within the company.

As of July 2020, we have collected 1705 documents and informational materials related to the policy environment affecting the development and management of COVID-19 medical products. Figure 1 below presents an overview of the distribution of documents by month, which demonstrates a rapid increase in documents or information released by authorities or bodies in the March and April timeframe, followed by a gradual decline of new documents or information released from May and onwards. This follows the trend of COVID-19 management efforts across the world when more information was required at the onset of the pandemic and subsequently lesser information in the later months as various approaches have been adopted to better manage the situation. Figure 2 shows the distribution by zone, with Asia-pacific having the highest number of documents issued. This is driven by New Zealand and Australia, respectively constituting 33% and 30% of the documents in the zone. China represents 13% of the total number of documents in the zone. The second largest zone by number of J o u r n a l P r e -p r o o f documents comes from Europe, of which 32% comes from European Union-level authorities such as the European Commission or the European Medicines Agency. Figure 3 provides a closer look of the distribution of these documents at national level; hence, excluding documents from regional (e.g. African Union, European Medicines Agency) and/or global bodies.

These documents were further classified according to type (Figure 4 ). Around 60% constitute documents that come in the form of communications (including announcement, notices, press releases and circulars), 22% guidances (including policies), 7% in the form of laws (including regulations, statutes, directives), and the rest as publications or other. In terms of topic area ( Figure 5 ), excluding the category 'other', most documents refer to information on clinical trials, safety, or multidisciplinary areas. The category 'other' refers to documents or information that could not be classified elsewhere e.g. agency operation and continuity, procurement, data protection, co-ordination mechanisms and platforms, meetings and response documents, amongst others.

From these documents and materials, we have identified 343 (or 20%), that refer to a regulatory agility or flexibility. Figure 6 and 7 provides an overview of the distribution by zone and by type. Using this data, we have extracted some information coupled with information from public databases, literature review, and our internal experiences and have identified the trends elaborated in the next section. To ensure that COVID-19-related medical products are rapidly assessed as potential treatments or vaccines, health authorities have considered expedited pathways 2 , either through an already existing pathway or as a new COVID-19-related emergency pathway 3 . Box 1 describes some examples of the various expedited pathways offered by regulators for COVID-19-related medical products.

( Table 1) In addition to those offered by the regulators at the country or regional level, two global pathways have been made available by the World Health Organization (WHO) to facilitate access of medical products in emergency situations. These two pathways include: 1) the WHO Emergency Use and Listing, which is an extraordinary process that aims to provide guidance to United Nations procurement agencies and regulators of WHO member states on the quality, safety, and performance of in-vitro diagnostics 4 ; and 2) the WHO prequalification program that aims to assess the quality, safety, and efficacy of medicinal products for priority diseases. 3,5

Approaches have also been adopted by regulators to facilitate the continuity of clinical trials for both COVID-19-related medical products and ongoing or planned studies outside of COVID-19. 6 Guidance on conducting clinical trials during the pandemic have been offered by several regulators 7, 8 ,9 ,10 , 11 -many of which are nonbinding and require effective monitoring from the sponsor and clinical investigators. These approaches ensure that patient safety remains paramount and that open communication is maintained across the various stakeholders involved in the clinical trial study. Some of these approaches are further described in Table 2 . 

Ensuring supply of medical products remains essential especially in emergency health situations, when the risk of shortages can be elevated. Simplified and exceptional management of regulatory processes have therefore been adopted by various regulators to maintain supply and lower the risk of such shortages. These have complemented industry's efforts such as in increasing production or donating medical products where needed. Expedited reviews have been offered (see Table 1) and have been useful especially for post-approval changes, such as in the case of the European Union's use of the exceptional change management process. 17 With regard to ensuring good practices, regulators have offered to conduct inspections remotely 18 or have granted sponsors with existing marketing authorization approval extensions, automatic re-certifications, or temporary certifications 17,19 .

The use of flexible approaches to labeling have also been widespread. For example, printed labels and packages adopted to a specific market may take a long time to be J o u r n a l P r e -p r o o f approved and then produced to ensure its availability during the pandemic. Some of the regulatory approaches proposed to address this issue include extending the permitted implementation time of the labeling update (except for significant safety updates) 20 , allowing non-local language labeling 21 , using electronic submissions of the packaging and leaflet instead of a physical sample 22 , or packing down of larger packs of medicinal products 23 .

In addition, open and transparent communication across stakeholders through virtual communication platforms and online notifications have proven useful in identifying any potential out-of-stock situations (e.g. FDA drug shortages database 24 and mobile app 25 ) as well as the creation of industry-agency task forces and working groups that allow for regular interactions between industry and regulators on shortages (e.g. the executive steering group on shortages and the industry single point of contact system in the EU 26 ).

This crisis has also increased collaboration across health authorities, industry, and between health authorities and industry. Various government-led partnerships and global consortia have been initiated to work together with industry and other stakeholders, such as academia, to accelerate the research and development of medical approaches to combatting COVID-19. 27 , 28 , 29 In addition to the various bilateral partnerships that have emerged at government or industry level, Table 3 presents some examples of multilateral partnerships and initiatives aiming to bring together efforts in building scientific knowledge and pooling resources to offer solutions to the pandemic. (Table 3) J o u r n a l P r e -p r o o f

Evidently, the current pandemic has also seen progress in the swift adoption of electronic platforms across many countries around the world -propelling stakeholders into a predominantly digital work mode. Based on information collected from our tracker and our experience when interacting with regulatory authorities, video calls have been used extensively, and even by default, to ensure regular interaction, while the cloud and other online storage tools have been utilized to store and share documents and information in real-time or more swiftly than prior to the pandemic. Some countries have also opted for online submissions of marketing authorization applications, such as through an email-based or online platform, notably where they have not been previously or extensively used.

While efforts to modernize regulatory processes through eliminating dated regulations, processes, or the waiving of supplementary requirements are not new, the pandemic has undoubtedly demonstrated that it is possible to reduce or even eliminate further some unnecessary administrative steps and requirements that can often be burdensome for both regulators and stakeholders involved in the process. Some approaches that have been introduced to lower the bureaucratic burden include:

• Issuance of electronic Certificate of Pharmaceutical Products (eCPP) that are signed and authenticated electronically 30 ;

• Acceptance of e-signatures 31 ;

• Waiving of legalizations/notarizations 32 , 33 , with the condition of submitting legalized documents after the COVID-19 pandemic 34 ; and

• Waiving of physical sample requirements 35, 36 J o u r n a l P r e -p r o o f

Many of the identified regulatory approaches have indeed been introduced temporarily to allow health authorities and stakeholders to manage the pandemic, in addition to ensuring the continuity of their respective operations. However, even with sustained operations, catching up on backlogs, delayed sponsor meetings, and other activities that had to be suspended during the pandemic constitute a challenge, as well as resuming activities that have not yet been extensively tested in a virtual environment prior to the current pandemic (e.g. remote inspections).

Furthermore, new priorities emerging from the pandemic, such as ensuring supply chain integrity and managing increasing fake medicines 37 , 38 , may require health authorities to also seek for additional tools and resources. In addition, the pandemic has impacted the implementation of some new provisions such as the EU implementation of the Medical Device Regulation 39 or Australia's adoption of TGO91 labels 40 , where resources have already been initially allocated.

These new and/or emerging challenges can be addressed by continuously leveraging agile approaches implemented during this pandemic. While these agile approaches have been triggered by COVID-19-, there is indeed additional opportunity to expand them beyond this current pandemic and to adopt them to other services or products that could also benefit all stakeholders involved, notably the patients.

COVID-19 has precipitated several opportunities that could be sustained beyond the pandemic. Based on the trends discussed above and the adoption of such approaches to date, five considerations in moving forward can be proposed: J o u r n a l P r e -p r o o f

Regulators have reacted quickly with the expedited issuance of relevant guidance during the acute phase of the pandemic, while making sure that these remain to meet quality requirements. This was especially useful to help industry understand "current" agency thinking and align approaches towards addressing the impact of the pandemic. To fully benefit from the gains achieved in the use of these agile regulatory approaches and extract lessons for the future, we believe it would be useful to conduct ex-post or post-implementation reviews. This would allow regulators to determine which specific approaches have resulted in the most gains across the sector and identify those that can be introduced temporarily during emergency situations or permanently adopted. Reviewing such approaches can help identify best practices that can be shared across regulatory authorities globally and allow for a closer examination to ensure regulatory mechanisms remain fit for purpose 41 and are increasingly harmonized.

Various ways of conducting ex-post evaluations can be pursued, such as in the form of programed review mechanisms or special purpose reviews 42 . Effective stakeholder engagement throughout this process will be essential in ensuring the uptake and implementation of any embedded regulatory approaches.

In order to accelerate innovation of treatments and vaccines to meet (unmet) medical needs for the benefit of patients, expedited review and approval pathways continued to play an important role during the COVID-19 pandemic especially among mature agencies. For example, the EMA implemented a rolling review tool to speed up the entire review process (see Table 1 ). Moreover, a study conducted in 2017 found that For example, lesser-resourced regulatory authorities, whose operations have been greatly impaired by the pandemic, can also benefit from insights from betterresourced regulatory authorities, and facilitate data sharing and approaches more broadly across different jurisdictions especially on product development, clinical trials, and marketing authorization.41 41, 50 Reliance and work-sharing approaches can be further explored, as suggested by the WHO. 51 A recently released WHO draft guidance on good reliance practices in regulatory decision-making provides some additional information and insights on how these practices can be implemented by regulators. 52 As various approaches are being pursued to test medical products during the COVID-19 pandemic, consistency and harmonization on the oversight, review, and management of clinical trials are important. 53 The OECD offers some binding recommendations on the governance of clinical trials, including facilitating international cooperation, which member states have agreed to abide by. 54 Approaches that facilitate the management and oversight of clinical trials, such as the use of remote clinical trials, can be further explored. 55, 56 Maintaining international co-operation across all stakeholders will be especially important for vaccines research and development, which can be a rather lengthy and complex process. 50, 57 Various approaches are already being pursued to speed up and support the clinical trial process, such as the use of remote clinical trials, econsent, and direct-to-patient delivery of investigational medicinal products. However, strengthened international regulatory cooperation with stakeholders should not only be limited to the current pandemic but must persist even post-pandemic.

Already existing approaches that simplify or facilitate certain regulatory processes, such as the use of electronic submissions and payments, digital signatures, or online platforms for meetings, discussions or information sharing are also some practices that can be retained or adopted more broadly.

Opportunities to adopt innovative digital technologies, platforms and tools can be further explored to propel the regulatory environment further into the future. These include data sharing tools such as the use of a cloud-based data system to support a more agile regulatory decision-making process 58 or processes facilitated by artificial intelligence 59 , amongst others.

Reducing the regulatory burden is a shared objective by all stakeholders, as it puts a strain on the limited resources available, and even more during emergency situations. This pandemic has provided us with the possibility to look closely into regulatory tools and approaches that simplify operations and reduce unnecessary administrative steps to deliver more efficient, forward-looking regulatory systems. The current pandemic provides us with lessons learned in addressing global emergency situations, and these experiences -both the challenges and solutions adopted -can be leveraged to prepare us for any future situations and can serve as an opportunity to reflect on current regulatory processes and tools. We propose that all relevant stakeholders work together to arrive at concrete proposals and actions in adopting learnings identified from agile approaches used during the COVID-19 crisis.

Initiatives to review learnings are already being undertaken by some health and regulatory authorities to embed this into future regulatory processes. In some instances, it may help agencies to leapfrog into contemporary approaches (i.e., maturing regulatory agencies looking into advancing their regulatory processes and systems and strengthening collaboration with other regulatory agencies and stakeholders).

The use of digital tools during the pandemic has also been remarkable and has facilitated the continuity of business operations. It has provided the opportunity for the pharmaceutical sector to re-evaluate the use of our tools to ensure they are able to facilitate the efficient functioning of regulatory processes and operations that ensure that medicines are developed and made available to patients. More J o u r n a l P r e -p r o o f importantly, this pandemic has underscored the importance and the benefit of working across all stakeholders, which can be continuously leveraged even postpandemic. A robust, coordinated approach will be beneficial, given the shared aim of ending this pandemic, ensuring a healthy population, and better managing emergency situations in the future.

The deployment of digital communication tools has seemingly lowered the barrier for communication and perhaps increased the frequency by which they have occurred, which has proven to be beneficial for all parties involved.

The use of agile regulatory approaches during the pandemic has helped ensure that medical products remained available, or that new ones could be effectively 

There are no conflicting interests to declare.

All authors hold positions within the pharmaceutical industry, but they have not received any grant, honoraria, or other compensation to author this paper. The study was conceived of, executed on, and written up in the course of the authors' daily job. • Rolling reviews A procedure that allows the regulator to assess data on a particular medical product as they are made available on a rolling basis. In the case of the EMA, this review procedure involves appointed CHMP rapporteurs during the development phase and the Agency reviewing the data on a rolling basis. This can be done through several review cycles. Each cycle lasts around two weeks depending on the data to be assessed until the data package is considered complete. Once complete, the sponsor can submit a formal marketing authorization application that is reviewed under a shorter timeline. .2

Regulators can grant a conditional marketing authorization for medical products where the immediate benefit outweighs the risk of having less available data than normally available. These are valid for one year and can be renewed annually, following specific obligations. 64 • Emergency use Regulators allow for the use of approved or unapproved medical products to diagnose, treat, or prevent serious and life-threatening diseases and conditions during an emergency when there are no adequate, approved, and available alternatives. 4,63,65

• Expanded access Also referred to as compassionate use, regulators allow for the use of an investigational medical product outside clinical trials for serious, immediately life-threatening diseases and conditions when no comparable, satisfactory alternative treatment is available. 66 pandemic. April 10, 2020. https://ec.europa.eu/health/sites/health/files/humanuse/docs/guidance_regulatory_covid19_en.pdf. Accessed August 4, 2020. 18 TGA. TGA expectations for overseas manufacturing sites hosting remote inspections during the COVID-19 pandemic. Australia Therapeutic Goods Administration. July 3, 2020. https://www.tga.gov.au/tga-expectations-overseasmanufacturing-sites-hosting-remote-inspections-during-covid-19-pandemic. Accessed August 7, 2020. 19 DC/ANVISA. Resolution No. 346 of 03/12/2020. Defines the extraordinary and temporary criteria and procedures for the certification of good manufacturing practices for the purposes of registration and post-registration changes of active pharmaceutical ingredient, medication and health products due to the international public health emergency of the new Coronavirus. Published in the DO on March 13, 2020. 20 HPRA. Variation Implementation Times for Labelling and Leaflet Updates to Human Medicines: Update on Regulatory Flexibility during the COVID-19 Pandemic. Health Products Regulatory Authority. May 18, 2020. http://www.hpra.ie/homepage/about-us/news-and-events/item?t=/variationimplementation-times-for-labelling-and-leaflet-updates-to-human-medicines-updateon-regulatory-flexibility-during-the-covid-19-pandemic&id=eb890d26-9782-6eee-9b55-ff00008c97d0#. Accessed August 5, 2020. 21 Swedish Medical Products Agency. Temporary regulations regarding language requirements for medical devices. May 20, 2020. https://www.lakemedelsverket.se/sv/nyheter/tillfalliga-foreskrifter-gallande-sprakkravfor-medicintekniska-produkter. Accessed August 5, 2020.

Information on the announcement and receipt of the final sample. National Institute of Pharmacy and Nutrition

Guidance for Manufacturers Specials licence holders on 'packing down' medicines during the coronavirus (COVID-19) outbreak. Medicines and Healthcare products Regulatory Agency

United States Food and Drug Administration

FDA. Drug Shortages. United States Food and Drug Authority

availability-medicines-during-covid-19-pandemic#enhanced-monitoring-system-for-medicines-used-for-treating-covid-19-section

NIH to launch public-private partnerships to speed COVID-19 vaccines and treatment options

CEPI collaborates with the Institut Pasteur in a Consortium to Develop COVID-19 Vaccine

Oxford University announces landmark partnership with AstraZeneca for the development of potential large-scale distribution od COVID-19 vaccine candidate

Information note on the format and validity features of electronic certificates for medicines issues by the European Medicines Agency

To the attention of all pharmaceutical companies. Turkey Medicines and Medical Devices Agency

Ministry of Public Health. Circular No. (6) Waiving off document legalization requirements

Submission of notarized/apostilled documents for import and registration of cosmetics in view of COVID-19 regarding

Physical samples for batch release not required: a reminder for sponsors of biosimilars and biological medicines

Re-Registration and Variation Applications During COVID-19 Pandemic. Food and Drugs Authority Ghana

COVID-19) and the global trade in fake pharmaceuticals

Global operation sees a rise in fake medical products related to COVID-19

European Commission proposes to delay MDR by a year due to COVID-19. RAPS Regulatory Focus

COVID-19 delays to adoption of TGO 91 labels. Australia Therapeutic Goods Administration

Global regulatory agility during COVID-19 and other health emergencies

Ex post evaluation of regulation: an Overview of the Notion and of International Practices. Regulatory Policy in Perspective: A Reader's Companion to the OECD Regulatory Policy Outlook

Drugs Cleared through the FDA's Expedited Review Offer Greater Gains than Drugs approved by Conventional Process

Health Canada's use of expedited review pathways and therapeutic innovation, 1995-2016: cross-sectional analysis

A Framework for evaluating and publicly designating regulatory authorities as WHO-Listed Authority (WLA) Interim list of National Regulatory Authorities

Pandemic Best Regulatory Practices: An Urgent Need in the COVID-19 Pandemic

From Print to Screen: Regulatory Considerations to Adopting Innovative Approaches for Patient Information and Safety

Addressing shortages of medicines

EFPIA. Policy Proposals to Minimise Medicine Supply Shortages in Europe

Working Hard or Hardly Working? Regulatory Bottlenecks in Developing a COVID-19 Vaccine

World Health Organization. Regulatory collaboration: collaboration, not competition: developing new reliance models

World Health Organization. Draft Working Document for Comments: Good reliance practices in regulatory decision-making: high-level principles and recommendations. Working document QAS/20.851

Greater harmonization of clinical trial regulations would help the fight against COVID-19. OECD Policy Responses to Coronavirus (COVID-19)

OECD. Recommendation of the Council on the Governance of Clinical Trials. OECD/LegalL0397. Adopted December 10

Remote Monitoring in Clinical Trials During the COVID-19 Pandemic

Beyond COVID-19: Modernizing Clinical Trial Conduct

Coronavirus Vaccine: Light at the End of the Tunnel

Cloud-based data systems in drug regulation: an industry perspective

Accessed August 10, 2020. 60 PAHO. Clinical Management of OVID-19

United States Food and Drug Administration

Health Canada. Priority Review of Drug Submissions

COVID-19: Regulatory Landscape of Medicinal and Medical Device Products for Human Use

Conditional marketing authorisation. European Medicines Agency

Emergency Use Authorization. United States Food and Drug Administration

United States Food and Drug Administration

United States Food and Drug Administration

html#:~:text=Operation%20Warp%20Speed%20(OWS)%20aims,(collectively %20known%20as%20countermeasures

United States Food and Drug Administration

Announcing the COVID-19 Therapeutics Accelerator

• Expedited reviews Reduction of timelines to the absolute minimum possible for products with major interest in public health. This encompasses priority reviews, fast track designations, and accelerated approvals. 2,61,62,63• Rolling reviews A procedure that allows the regulator to assess data on a particular medical product as they are made available on a rolling basis. In the case of the EMA, this review procedure involves appointed CHMP rapporteurs during the development phase and the Agency reviewing the data on a rolling basis. This can be done through several review cycles. Each cycle lasts around two weeks depending on the data to be assessed until the data package is considered complete. Once complete, the sponsor can submit a formal marketing authorization application that is reviewed under a shorter timeline. 2

Regulators can grant a conditional marketing authorization for medical products where the immediate benefit outweighs the risk of having less available data than normally available. These are valid for one year and can be renewed annually, following specific obligations. 64 • Emergency use Regulators allow for the use of approved or unapproved medical products to diagnose, treat, or prevent serious and life-threatening diseases and conditions during an emergency when there are no adequate, approved, and available alternatives. 4,6,65• Expanded access Also referred to as compassionate use, regulators allow for the use of an investigational medical product outside clinical trials for serious, immediately life-threatening diseases and conditions when no comparable, satisfactory alternative treatment is available. 66 ,67

The US FDA's special emergency program that aims to use every available method to facilitate the discovery and development of new treatments for COVID-19. 68 • • COVID-19 Therapeutics Accelerator Launched by the Bill & Melinda Gates Foundation, Wellcome, and Mastercard, this platform aims to support the acceleration and evaluation of new and repurposed medicines and vaccines to treat patients with COVID-19, and ensure equitable access by making these available and affordable notably in low-resource settings. 71